Gail V Matthews1, Sanjay Bhagani2, Marc Van der Valk3, Juergen Rockstroh4, Jordan J Feld5, Andri Rauch6, Christine Thurnheer6, Julie Bruneau7, Arthur Kim8, Margaret Hellard9, David Shaw10, Ed Gane11, Mark Nelson12, Patrick Ingiliz13, Tanya L Applegate14, Jason Grebely14, Phillipa Marks14, Marianne Martinello14, Kathy Petoumenos14, Gregory J Dore15. 1. Kirby Institute, UNSW Sydney, Australia; St Vincent's Hospital, Sydney, Australia. Electronic address: gmatthews@kirby.unsw.edu.au. 2. Royal Free Hospital, London, United Kingdom. 3. Amsterdam University Medical Centers, Academic Medical Center, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands. 4. University Clinic Bonn, Bonn, Germany. 5. Toronto Centre for Liver Diseases, Toronto General Hospital, Toronto, Canada. 6. Department of Infectious Diseases, Inselspital, Bern, Switzerland. 7. Centre Hospitalier de l'Université de Montréal, Montréal, Canada. 8. Division of Infectious Diseases, Massachusetts General Hospital, Boston, United States. 9. The Alfred Hospital, Melbourne, Australia; The Burnet Institute, Melbourne, Australia. 10. Royal Adelaide Hospital, Adelaide, Australia. 11. Auckland City Hospital, Auckland, New Zealand. 12. Chelsea & Westminster Hospital, London, United Kingdom. 13. Zentrum für Infektiologie Berlin-Prenzlauer Berg, Berlin, Germany. 14. Kirby Institute, UNSW Sydney, Australia. 15. Kirby Institute, UNSW Sydney, Australia; St Vincent's Hospital, Sydney, Australia.
Abstract
BACKGROUND & AIMS: Shortened duration therapy for acute and recent HCV infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens; however, large randomised studies are lacking. METHODS: REACT was an NIH-funded multicentre international, open-label, randomised, phase IV non-inferiority trial examining the efficacy of short course (6-week) vs. standard course (12-week) therapy with sofosbuvir-velpatasvir for recent HCV infection (estimated duration of infection ≤12 months). Randomisation occurred at week 6. The primary endpoint was sustained virological response 12 weeks after treatment end (SVR12) in the intention-to treat (ITT) population. A total of 250 participants were due to be enrolled, but on advice of the data safety and monitoring board the study was halted early. RESULTS: The primary analysis population consisted of 188 randomised participants at termination of study enrolment; short arm (n = 93), standard arm (n = 95). Ninety-seven percent were male and 69% HIV positive. ITT SVR12 was 76/93, 81.7% (95% CI 72.4-89.0) in the short arm and 86/95, 90.5% (95% CI 82.7-95.6) in the standard arm. The difference between the arms was -8.8 (95% CI -18.6 to 1.0). In modified ITT analysis, wherein non-virological reasons for failure were excluded (death, reinfection, loss to follow-up), SVR12 was 76/85, 89.4% (95% CI 80.8-95.0) in the short arm and 86/88, 97.7% in the standard arm (95% CI 92.0-99.7; difference -8.3%, p = 0.025). CONCLUSIONS: In this randomised study in recent HCV infection, a 6-week course of sofosbuvir-velpatasvir did not meet the criteria for non-inferiority to standard 12-week therapy. LAY SUMMARY: In this randomised trial, 188 people with recently acquired hepatitis C infection were randomly assigned to treatment using either a short 6-week course (93 people) or standard 12-week course (95 people) of the hepatitis C treatment sofosbuvir/velpatasvir. There were 9 cases of relapse after treatment with the short course and 2 following the standard course. A shortened course of 6-week therapy for hepatitis C infection appeared to be less effective than a standard 12-week course in people with recently acquired hepatitis C infection. CLINICALTRIALS. GOV IDENTIFIER: NCT02625909.
BACKGROUND & AIMS: Shortened duration therapy for acute and recent HCV infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens; however, large randomised studies are lacking. METHODS: REACT was an NIH-funded multicentre international, open-label, randomised, phase IV non-inferiority trial examining the efficacy of short course (6-week) vs. standard course (12-week) therapy with sofosbuvir-velpatasvir for recent HCV infection (estimated duration of infection ≤12 months). Randomisation occurred at week 6. The primary endpoint was sustained virological response 12 weeks after treatment end (SVR12) in the intention-to treat (ITT) population. A total of 250 participants were due to be enrolled, but on advice of the data safety and monitoring board the study was halted early. RESULTS: The primary analysis population consisted of 188 randomised participants at termination of study enrolment; short arm (n = 93), standard arm (n = 95). Ninety-seven percent were male and 69% HIV positive. ITT SVR12 was 76/93, 81.7% (95% CI 72.4-89.0) in the short arm and 86/95, 90.5% (95% CI 82.7-95.6) in the standard arm. The difference between the arms was -8.8 (95% CI -18.6 to 1.0). In modified ITT analysis, wherein non-virological reasons for failure were excluded (death, reinfection, loss to follow-up), SVR12 was 76/85, 89.4% (95% CI 80.8-95.0) in the short arm and 86/88, 97.7% in the standard arm (95% CI 92.0-99.7; difference -8.3%, p = 0.025). CONCLUSIONS: In this randomised study in recent HCV infection, a 6-week course of sofosbuvir-velpatasvir did not meet the criteria for non-inferiority to standard 12-week therapy. LAY SUMMARY: In this randomised trial, 188 people with recently acquired hepatitis C infection were randomly assigned to treatment using either a short 6-week course (93 people) or standard 12-week course (95 people) of the hepatitis C treatment sofosbuvir/velpatasvir. There were 9 cases of relapse after treatment with the short course and 2 following the standard course. A shortened course of 6-week therapy for hepatitis C infection appeared to be less effective than a standard 12-week course in people with recently acquired hepatitis C infection. CLINICALTRIALS. GOV IDENTIFIER: NCT02625909.
Authors: Marcus Bülow; Norman Best; Sebastian Brugger; Steffen Derlien; Dana Loudovici-Krug; Christina Lemhöfer Journal: Eur Arch Otorhinolaryngol Date: 2022-09-14 Impact factor: 3.236
Authors: Ethel D Weld; Jacqueline Astemborski; Gregory D Kirk; Mark S Sulkowski; Stephanie Katz; Richard Rothman; Sunil S Solomon; Gail V Matthews; Yu Hsiang Hsieh; Malvika Verma; Giovanni Traverso; Susan Swindells; Andrew Owen; Jordan Feld; Charles Flexner; Shruti H Mehta; David L Thomas Journal: Clin Infect Dis Date: 2022-08-24 Impact factor: 20.999
Authors: Lone W Madsen; Peer B Christensen; Janne F Hansen; Birgit T Røge; Dorte K Holm; Sandra Dröse; Anne Øvrehus Journal: Viruses Date: 2022-03-16 Impact factor: 5.048